Results 171 to 180 of about 325,665 (311)

Third activity report for the year ending June 2002. Report by the European Anti-Fraud Office [PDF]

, 2002

core  

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Arab Medical Tourists in Iran: A Phenomenological Study of Lived Experience. [PDF]

Health Sci Rep
Shaygani F, Marzaleh MA, Movahed PD, Bahrami MA, Mohamadpour M, Delavari S.   +5 more
europepmc   +1 more source

STATE FINANCIAL CONTROL IN CUSTOMS AUTHORITIES

AZIMUTH OF SCIENTIFIC RESEARCH: ECONOMICS AND ADMINISTRATION, 2019
openaire   +2 more sources

Annual overview with information on the results of the Hercule II Programme in 2012 (Article 7 of Decision 878/2007 of 23 July 2007). Commission staff working document accompanying the report on the fight against fraud 2012. SWD (2013) 287 final, 24 July 2013 [PDF]

, 2013

core  

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

The 100 Days Mission: a perspective on accelerating vaccine manufacturing for future pandemics. [PDF]

BMC Glob Public Health
Williams BA, Fitzsimmons PM, Lewis LM, Tornos J, Kimmel L, True JM, Siwik PJ, Ryall M, Mullett K.   +8 more
europepmc   +1 more source

Report on the follow-up of traditional own resources in cases of fraud and irregularities. Report from the Commission. COM (2004) 850 final/2, 4 February 2005 [PDF]

, 2005

core  

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Open carry. [PDF]

Fly (Austin)
Jacobs H.
europepmc   +1 more source